Apply to trial NCT06731933

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin

The study objective is to see if BVEC induced C7 expression in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin following Squamous cell carcinoma (SCC) excision will normalize the invasive tumor microenvironment and reduce tumor recurrence. Prevention of SCC's in the RDEB subjects will increase their life span.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening